8-K: Orgenesis Inc. Stockholders Approve Increase in Equity Incentive Plan Shares and Elect Directors at 2024 Annual Meeting

Orgenesis Inc. held its 2024 annual meeting where stockholders approved an increase of 9,000,000 shares to the 2017 Equity Incentive Plan and elected five directors.

Summary

• Orgenesis Inc. held its 2024 annual meeting of stockholders on June 27, 2024.
• Stockholders approved an amendment to the 2017 Equity Incentive Plan, increasing the number of shares available for grant by 9,000,000 shares.
• Five director nominees were elected to serve until the 2025 annual meeting.
• The company's independent registered public accounting firm, Kesselman & Kesselman C.P.A.s, was ratified for the fiscal year ending December 31, 2024.
• A quorum of approximately 43% of outstanding shares was present at the meeting.
• Three directors, Guy Yachin, Dr. David Sidransky, and Mario Philips, did not stand for re-election, ending their terms on the board.

Sentiment

Score: 7

Explanation: The document reflects standard corporate governance activities with no major positive or negative surprises. The increase in the equity plan is a positive for future talent acquisition, but the departure of three directors is a minor concern.

Positives

• Stockholders approved the increase in shares for the equity incentive plan, which can be used to attract and retain talent.
• The election of five directors provides stability and continuity for the company's governance.
• The ratification of the independent auditor ensures financial oversight for the company.

Negatives

• Three directors did not stand for re-election, resulting in a change in the composition of the board.
• One director nominee, Kevin Choquette, withdrew his nomination prior to the meeting.

Risks

• The departure of three directors could potentially impact the company's strategic direction.
• The withdrawal of a director nominee may indicate internal issues or challenges.

Future Outlook

The newly elected directors will serve until the 2025 annual meeting of stockholders.

Management Comments

• The decision of each of Mr. Yachin, Dr. Sidransky and Mr. Philips not to stand for re-election was not the result of any disagreement between the Company and themselves on any matter relating to the Company's operations, policies or practices.

Industry Context

The approval of the equity incentive plan amendment is a common practice for companies to attract and retain talent in the competitive biotech industry. The director elections are a routine part of corporate governance.

Comparison to Industry Standards

• The increase of 9,000,000 shares for the equity incentive plan is within the typical range for companies of similar size and stage in the biotech industry. For example, comparable companies such as Cellectis and CRISPR Therapeutics have similar equity incentive plans to attract and retain key personnel.
• The director election process and the ratification of an independent auditor are standard corporate governance practices, aligning with the practices of other publicly traded companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals.
• The level of shareholder participation, with approximately 43% of shares represented, is within the expected range for annual meetings of companies of this size. This is comparable to other biotech companies such as bluebird bio and Alnylam Pharmaceuticals.

Management Changes

Stakeholder Impact

• Shareholders have approved key governance matters, including the equity plan and director elections.
• Employees may benefit from the increased share availability in the equity incentive plan.
• The company's management and board are now set for the next year.

Next Steps

• The newly elected directors will begin their terms on the board.
• The company will implement the amended 2017 Equity Incentive Plan.
• The company will continue to operate under the oversight of the ratified independent auditor.

Key Dates

Keywords

equity incentive plan, annual meeting, directors, stockholders, corporate governance, board of directors, auditor, Kesselman & Kesselman, stock options